Positive Outlook For J&J’s Multiple Myeloma Portfolio Following Latest Regulatory Developments
Pharmaceuticals / United States / Tue 27 Feb, 2024
Key View
- Recent positive regulatory developments in Europe and the US will enhance J&J’s multiple myeloma drug portfolio.
- J&J’s multiple myeloma drug, Carvykti, will outperform Bristol-Myers Squibb’s Abecma, its closest competitor, further strengthening J&J’s oncology business.
- The FDA’s growing caution of CAR T-cell therapies will pose